Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Àü¸³¼±¿°ÁõÈıº ȯÀÚ¿¡¼­ ¹è´¢Áõ»óÁ¡¼ö¿Í ¿ä¼Ó°Ë»çÀÇ À¯¿ë¼º Usefulness of Voiding Symptom Score and Uroflowmetry as the Screening Methods for Patients with Prostatitis Syndrome

´ëÇѺñ´¢±â°úÇÐȸÁö 1998³â 39±Ç 3È£ p.259 ~ 265
Á¤µµ¿µ, ÀÌÁ¤±¸, ±è¿µ¼ö,
¼Ò¼Ó »ó¼¼Á¤º¸
Á¤µµ¿µ (  ) 
¾ÆÁÖ´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç

ÀÌÁ¤±¸ (  ) 
°í·Á´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç
±è¿µ¼ö (  ) 
¾ÆÁÖ´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç

Abstract

¼­·Ð
Àü¸³¼±¿°ÁõÈıº Áß ¼¼±Õ°¨¿°ÀÌ È®ÀεǴ ±Þ, ¸¸¼º¼¼±Õ¼ºÀü¸³¼±¿°Àº Ç×»ýÁ¦Ä¡·á°¡ È¿°úÀû
ÀÌÁö¸¸, Àü¸³¼±¿°ÁõÈıº ȯÀÚÀÇ ´ëºÎºÐÀ» Â÷ÁöÇÏ´Â ºñ¼¼±Õ¼ºÀü¸³¼±¿°°ú Àü¸³¼±ÅëÀº Àå±â°£
ÀÇ Ç×»ýÁ¦ Ä¡·á¿¡µµ ºÒ±¸ÇÏ°í Áõ»óÀÌ Áö¼ÓµÇ´Â °æ¿ì°¡ ¸¹¾Æ, ±× ¹ß»ý¿øÀΰú Ä¡·á¹æ¹ý¿¡ ´ë
ÇØ ´Ù¾çÇÑ ¿¬±¸°¡ º¸°íµÇ°í ÀÖ´Ù.
ºñ¼¼±Õ¼ºÀü¸³¼±¿°ÀÇ ¿øÀÎÀ¸·Î ¼¼±ÕÀÌ¿ÜÀÇ ¹Ì»ý¹°À̳ª ÀÚ°¡¸é¿ªÁúȯÀÇ °¡´É¼ºÀÌ Á¦½ÃµÇ±âµµ
ÇÏÁö¸¸, Àü¸³¼±³»·ÎÀÇ ¿ä¿ª·ùÇö»ó¿¡ ÀÇÇÑ È­ÇÐÀû ¿°Áõ¹ÝÀÀÀÌ Á¡Á¡ ¿ì¼¼ÇÑ ¹ß»ý¿øÀÎÀ¸·Î Á¦
½ÃµÇ°í ÀÖÀ¸¸ç ÀÌ Çö»óÀº ºñ¼¼±Õ¼ºÀü¸³¼±¿°°ú À¯»çÇÑ Àü¸³¼±ÅëÀÇ ÇÑ ¿øÀÎÀ¸·Îµµ Ç®ÀÌ µÇ°í
ÀÖ´Ù.
Àü¸³¼±³»·ÎÀÇ ¿ä¿ª·ùÇö»óÀº Àü¸³¼±¿äµµ ºÎÀ§ÀÇ ³»¾ÐÀÌ »ó½ÂµÉ ¶§¿¡ ¹ß»ýÇϸç, ¿äµµ³»¾ÐÀÇ
»ó½ÂÀº ÁÖ·Î ÇϺοä·ÎÀÇ ±â´ÉÀû ¶Ç´Â ÇغÎÇÐÀû ÀÌ»ó¿¡ ÀÇÇÑ ¹è´¢Àå¾Ö ½Ã¿¡ ¹ß»ýµÈ´Ù. µû¶ó
¼­ Àü¸³¼±¿°ÁõÈıº°ú ¹è´¢Àå¾Ö´Â ¿¬°ü¼ºÀ» °¡Áø´Ù°í ÇÒ ¼ö ÀÖÀ¸³ª ÀÌ¿¡ ´ëÇÑ ¿¬±¸º¸°í´Â µå
¹® ½ÇÁ¤ÀÌ´Ù. ¶ÇÇÑ ÃÖ±Ù¿¡´Â ÆòÈ°±Ù ±³°¨½Å°æ Â÷´ÜÁ¦°¡ ÀϺΠÀü¸³¼±¿°ÁõÈıº ȯÀÚ¿¡¼­ È¿°ú
ÀûÀÎ °ÍÀ¸·Î º¸°íµÇ°í ÀÖÀ¸³ª È¿°úÀûÀΠȯÀÚ¼±ÅÃÀÇ ±âÁØÀÌ ¼³Á¤µÇ¾î ÀÖÁö´Â ¾Ê´Ù.
ÀÌ¿¡ ÀúÀÚµéÀº Àå±â°£ÀÇ Ç×»ýÁ¦Ä¡·á¿¡µµ Å« È¿°ú¸¦ ±â´ëÇÒ ¼ö ¾ø´Â ºñ¼¼±Õ¼ºÀü¸³¼±¿°ÁõÈÄ
±ºÀÇ Áõ»óÀ¸·Î ³»¿øÇÑ È¯ÀÚ¿¡¼­ ¹è´¢Àå¾ÖÀÇ ¼±º°°Ë»ç¹ýÀÎ IPSS(inter-national prostate
symptom scone)Áõ»óÁ¡¼ö¿Í ¿ä¼Ó°Ë»ç¸¦ ½ÃÇàÇÑ ÈÄ, Áõ»óÀÇ Æ¯Â¡°ú ¹è´¢Àå¾ÖÀÇ µ¿¹ÝÁ¤µµ ¹×
ÀÌ¿¡ µû¸¥ ±³°¨½Å°æÂ÷´ÜÁ¦ÀÇ Ä¡·áÈ¿°ú¸¦ ºÐ¼®ÇÏ¿© IPSSÁõ»óÁ¡¼ö¿Í ¿ä¼Ó°Ë»ç°¡ ºñ¼¼±Õ¼ºÀü
¸³¼±¿°ÁõÈıº ȯÀÚ¸¦ À§ÇÑ ¼±º°°Ë»ç·Î¼­ À¯¿ëÇÑÁö¿Í ¾î´À °æ¿ì¿¡ ±³°¨½Å°æÂ÷´ÜÁ¦°¡ È¿°úÀû
ÀÎÁö¸¦ ¾Ë¾Æº¸°íÀÚ ÇÏ¿´´Ù. ¶ÇÇÑ Â÷Èİ˻翡¼­ ¹àÇôÁø ±âŸ ¹è´¢Àå¾Ö Áúȯ¿¡¼­ ³ªÅ¸³ª´Â Ư
¡µµ ¾Ë¾Æº¸¾Ò´Ù.
#ÃÊ·Ï#
Purpose: Recently, urine reflux into prostate during abnormal micturition has been
proved and suggested to be an important pathogenetic factor that evoked the symptoms
of prostatitis syndrome. The evaluation of voiding dysfunction in these patients may
give the useful information to select the treatment methods or the next step of study.
The objectives of this study was to evaluate the usefulness of voiding symptom score
and uroflowmetry as the screening methods for patients with nonbacterial prostatitis
syndrome.
Materials and Methods: For patients with prostatitis syndrome, evaluations of urine,
prostatic secretion, voiding symptom scores(IPSS: international prostate symptoms score),
and uroflowmetry were performed. Patients were divided into 3 groups according to the
patterns of uroflow curve[type N; normal bell shape with Qmax(maximal flow
rate)>20m1/sec, type I; irregular shape, regardless of Qmax, type P; plateau shape with
Qmaxf15m1/sec]. For patients with cutie patterns of type I and p, G-blockers were tried
initially for 1-2 months and the effectiveness of o-blockers according to the changes of
IPSS, Qmax and patterns of uroflow cutie was estimated. Patients with the pattern of
type N and non-responders to o-blockers were further investigated to rule out any other
cause.
Results: Among total 64 patients, 55 patients(86%) showed the abnormal uroflow
cuties(Type I or P). 34(61.8%) of these 55 patients responded to ¥á-blockers with
changes of IPSS from 18.3 to 8.1(p<0.001) and of Qmax from 13.gm1/sec to
20.0ml/sec(p<0.001). The response to o-blockers was expected highly in group of type I
with more than 10m1/sec of Qmax and less than 20points of IPSS(14.7folds). Of the 9
of type N patients, 6 were revealed to have idiopathic detrusor instability and 18 of 21
non-responders to ¥á-blockers were diagnosed to have the bladder neck obstruction.
Conclusions: The results that the effectiveness to o-blockers and the possibility of
other disease could be characterized by IPSS and uroflowmetry suggest IPSS and
uroflowmetry may be the useful screening methods for patients with prostatitis
syndrome.

Å°¿öµå

Prostatitis syndrome; Symptom score; Uroflowmetry;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS